COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00122317
Recruitment Status : Completed
First Posted : July 22, 2005
Results First Posted : June 5, 2017
Last Update Posted : March 13, 2018
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.

Condition or disease Intervention/treatment Phase
Paroxysmal Hemoglobinuria, Nocturnal Drug: eculizumab Phase 3

Detailed Description:
An open-label extension study to evaluate long-term safety of eculizumab in PNH patients who had completed the TRIUMPH (C04-001), SHEPHERD (C04-002), and X03-001 studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 187 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Actual Study Start Date : May 2005
Actual Primary Completion Date : September 2008
Actual Study Completion Date : October 2008

Arm Intervention/treatment
Experimental: Eculizumab
600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
Drug: eculizumab
Other Name: Soliris

Primary Outcome Measures :
  1. Incidence of Treatment-emergent Adverse Events [ Time Frame: From time of consent to a maximum of 2.5 years of study treatment ]

Secondary Outcome Measures :
  1. Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve [ Time Frame: From time of first infusion through 24 months of study treatment ]
  2. Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline [ Time Frame: From time of first infusion through 24 months of study treatment ]
    The FACIT-Fatigue scale is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.

  3. Incidence of Thrombosis After Eculizumab Infusion [ Time Frame: From time of first ever dose through last dose (up to 24 months of study treatment) ]
    Thrombosis was defined as occurrence of major adverse vascular events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have fully completed the TRIUMPH, SHEPHERD, or X03-001 studies
  • TRIUMPH patients who have discontinued receiving investigational drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures
  • Patient must be willing and able to give written informed consent
  • Patient must avoid conception during the trial

Exclusion Criteria:

  • Patients who have terminated early from the SHEPHERD or X03-001 studies
  • Patients who have terminated early from the TRIUMPH study due to an adverse event
  • Female who is pregnant, breast feeding, or intending to conceive during the course of the study
  • Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00122317

Show Show 40 study locations
Sponsors and Collaborators
Alexion Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals Identifier: NCT00122317    
Other Study ID Numbers: E05-001
First Posted: July 22, 2005    Key Record Dates
Results First Posted: June 5, 2017
Last Update Posted: March 13, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Alexion Pharmaceuticals:
transfusion dependent
paroxysmal nocturnal hemoglobinuria
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinuria, Paroxysmal
Urination Disorders
Urologic Diseases
Urological Manifestations
Anemia, Hemolytic
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases